• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性高血压中的微量白蛋白尿。不同降压药物的降低作用。

Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.

作者信息

Erley C M, Haefele U, Heyne N, Braun N, Risler T

机构信息

University of Tübingen, Department of Nephrology and Hypertension, FRG.

出版信息

Hypertension. 1993 Jun;21(6 Pt 1):810-5. doi: 10.1161/01.hyp.21.6.810.

DOI:10.1161/01.hyp.21.6.810
PMID:8500862
Abstract

The effects of four different antihypertensive drugs (the Ca(2+)-channel blocker felodipine, the beta-blocker metoprolol, the angiotensin converting enzyme inhibitor ramipril, and the alpha-blocking agent doxazosin) on microalbuminuria and renal hemodynamics were evaluated in a double-blind, crossover study in 17 patients (10 women, seven men, aged 39 +/- 14 years) with mild-to-moderate essential arterial hypertension and microalbuminuria. Patients were studied after a 2-week placebo phase preceded by 2 weeks off all medication and after 12 weeks of treatment with each drug. Between each drug treatment, there was another 14-day placebo washout period. At the end of the study, we performed two additional 2-week placebo periods. After each placebo and treatment period, we measured albumin excretion during a 3-day collecting period. Renal hemodynamics were assessed by clearance techniques (inulin and p-aminohippurate clearance) at the end of the first and last placebo periods and after each treatment period. All drugs reduced mean arterial pressure and microalbuminuria to a similar and statistically significant (p < 0.05) extent (mean arterial pressure: placebo phase, 116 +/- 5 mm Hg; felodipine, 101 +/- 4 mm Hg; metoprolol, 101 +/- 5 mm Hg; ramipril, 101 +/- 4 mm Hg; doxazosin, 102 +/- 5 mm Hg; urinary albumin excretion: placebo phase, 46 +/- 50 mg/day; felodipine, 18 +/- 23 mg/day; metoprolol, 14 +/- 12 mg/day; ramipril, 16 +/- 16 mg/day; doxazosin, 14 +/- 14 mg/day). Mean arterial pressure levels and urinary albumin excretion returned to baseline after the last placebo period (110 +/- 6 mm Hg and 40 +/- 46 mg/day, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在一项双盲、交叉研究中,对17例(10名女性,7名男性,年龄39±14岁)患有轻至中度原发性高血压和微量白蛋白尿的患者,评估了四种不同降压药物(钙通道阻滞剂非洛地平、β受体阻滞剂美托洛尔、血管紧张素转换酶抑制剂雷米普利和α受体阻滞剂多沙唑嗪)对微量白蛋白尿和肾脏血流动力学的影响。患者在停用所有药物2周后经过2周的安慰剂阶段,然后接受每种药物治疗12周。在每种药物治疗之间,还有一个14天的安慰剂洗脱期。在研究结束时,又进行了两个为期2周的安慰剂阶段。在每个安慰剂期和治疗期结束后,我们在3天的收集期内测量白蛋白排泄量。在第一个和最后一个安慰剂期结束时以及每个治疗期后,通过清除技术(菊粉和对氨基马尿酸清除率)评估肾脏血流动力学。所有药物均将平均动脉压和微量白蛋白尿降低到相似且具有统计学意义(p<0.05)的程度(平均动脉压:安慰剂阶段,116±5mmHg;非洛地平,101±4mmHg;美托洛尔,101±5mmHg;雷米普利,101±4mmHg;多沙唑嗪,102±5mmHg;尿白蛋白排泄量:安慰剂阶段,46±50mg/天;非洛地平,18±23mg/天;美托洛尔,14±12mg/天;雷米普利,16±16mg/天;多沙唑嗪,14±14mg/天)。在最后一个安慰剂期后,平均动脉压水平和尿白蛋白排泄量恢复到基线(分别为110±6mmHg和40±46mg/天)。(摘要截断于250字)

相似文献

1
Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.原发性高血压中的微量白蛋白尿。不同降压药物的降低作用。
Hypertension. 1993 Jun;21(6 Pt 1):810-5. doi: 10.1161/01.hyp.21.6.810.
2
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.强化降压对原发性高血压患者肾功能及白蛋白排泄的影响。在长期β受体阻滞剂治疗基础上加用非洛地平或雷米普利。
Am J Hypertens. 1995 Feb;8(2):113-23. doi: 10.1016/0895-7061(94)00174-A.
3
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.雷米普利与美托洛尔降压治疗对常染色体显性多囊肾病的肾脏和心脏影响
Nephrol Dial Transplant. 2008 Feb;23(2):573-9. doi: 10.1093/ndt/gfm731. Epub 2007 Nov 4.
4
A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.赖诺普利与阿替洛尔对单纯原发性高血压患者低度尿白蛋白排泄、肾功能及血流动力学影响的比较研究
Eur J Clin Pharmacol. 1992;43(5):469-75. doi: 10.1007/BF02285087.
5
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.氨氯地平/雷米普利联合用药与氨氯地平单药治疗高血压的18周前瞻性随机双盲多中心研究:氨氯地平/雷米普利联合治疗评估(ATAR)研究
Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.
6
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).乐卡地平与雷米普利相比对伴有微量白蛋白尿的高血压2型糖尿病患者白蛋白排泄率的影响:DIAL研究(糖尿病、高血压、白蛋白尿、乐卡地平)
Diabetes Nutr Metab. 2004 Oct;17(5):259-66.
7
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.低剂量雷米普利对血压正常或轻度高血压的非胰岛素依赖型糖尿病患者微量白蛋白尿的影响。意大利东北部微量白蛋白尿研究组。
Am J Hypertens. 1995 Sep;8(9):876-83. doi: 10.1016/0895-7061(95)00162-i.
8
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.肾素-血管紧张素系统双重阻断治疗高血压、微量白蛋白尿及非胰岛素依赖型糖尿病患者的随机对照试验:坎地沙坦与赖诺普利微量白蛋白尿(CALM)研究
BMJ. 2000 Dec 9;321(7274):1440-4. doi: 10.1136/bmj.321.7274.1440.
9
Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.
Am J Nephrol. 1997;17(1):72-80. doi: 10.1159/000169075.
10
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?非洛地平-美托洛尔复方片剂:启动抗高血压治疗的一个有价值的选择?
Am J Hypertens. 1999 Sep;12(9 Pt 1):915-20. doi: 10.1016/s0895-7061(99)00067-9.

引用本文的文献

1
Renal clearance estimated by rubidium-82 positron emission tomography/computed tomography and technetium-99m-mercaptoacetyltriglycine clearance infusion technique.通过铷-82正电子发射断层扫描/计算机断层扫描和锝-99m-巯基乙酰三甘氨酸清除率输注技术估算的肾清除率。
Clin Physiol Funct Imaging. 2025 Mar;45(2):e70000. doi: 10.1111/cpf.70000.
2
The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage.致病性淀粉样前体蛋白(APP)N端Val225Ala突变改变tau蛋白的液-液相分离并加剧突触损伤。
Mol Psychiatry. 2025 Jun;30(6):2316-2334. doi: 10.1038/s41380-024-02837-6. Epub 2024 Nov 18.
3
Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.
非糖尿病慢性肾脏病的药物性肾保护——波兰肾脏病学会临床实践立场声明
J Clin Med. 2023 Aug 9;12(16):5184. doi: 10.3390/jcm12165184.
4
Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.α-和β-肾上腺素能信号在表型靶向中的作用:在良性和恶性泌尿科疾病中的意义。
Cell Commun Signal. 2021 Jul 20;19(1):78. doi: 10.1186/s12964-021-00755-6.
5
Impact of Serum Uric Acid Levels on Outcomes following Renal Artery Revascularization in Patients with Renovascular Disease.血清尿酸水平对肾血管疾病患者肾动脉血运重建术后结局的影响。
Int J Hypertens. 2019 Jan 30;2019:3872065. doi: 10.1155/2019/3872065. eCollection 2019.
6
Management of Hypertension in Chronic Kidney Disease.高血压合并慢性肾脏病的管理。
Drugs. 2019 Mar;79(4):365-379. doi: 10.1007/s40265-019-1064-1.
7
Microalbuminuria in hypertension.高血压中的微量白蛋白尿
Curr Hypertens Rep. 2003 Jun;5(3):208-14. doi: 10.1007/s11906-003-0022-0.
8
The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.抗高血压药物组对非糖尿病患者人群尿白蛋白排泄的影响。
Br J Clin Pharmacol. 2002 Jan;53(1):31-6. doi: 10.1046/j.0306-5251.2001.01503.x.
9
Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.喹那普利:其在心血管疾病中的药理学及治疗应用的进一步更新
Drugs. 2002;62(2):339-85. doi: 10.2165/00003495-200262020-00009.
10
Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.非洛地平/美托洛尔:关于固定剂量控释制剂治疗原发性高血压的综述
Drugs. 2000 Jan;59(1):141-57. doi: 10.2165/00003495-200059010-00011.